Ibrutinib is a Bruton's tyrosine kinase (BTK) inhibitor that binds to and irreversibly inhibits BTK activity, thereby preventing both B-cell activation and B-cell-mediated signaling, which may result to decreased growth of cancer cells.
| SparkCures ID | 31 |
|---|---|
| Developed By | Pharmacyclics |
| Generic Name | Ibrutinib |
| Additional Names | Imbruvica, PCI-32765 |
| Treatment Classifications |
View all active clinical trials around the US.
There are no resources, links or videos to display for this treatment.